Sulfateq is an innovative privately-held biotechnology company whose mission is to bring innovative treatments to patients in a wide range of therapeutic indications related to mitochondrial dysfunction. Inspired by natures natural mechanisms to cope with mitochondrial stress, Sulfateq develops phenotypic screening assays that allow for the discovery of new chemical entities that improve mitochondrial function during chronic non-communicable diseases disease.

Sulfateq is an early-stage biotech that specializes in the discovery and development of first-in-class small molecules that facilitate mitochondrial respiration (i.e. ATP production), mitigate mitochondrial damage or limit mitochondrial oxidative stress. Sulfateq’ s lead compounds SUL-138, SUL-150 and SUL-151 are orally bioavailable and effective in preclinical models of diabetic kidney disease, chronic obstructive pulmonary disease, heart failure and neurodegeneration. In these disease areas, a strong medical need exists in these disease areas, as currently approved treatments are symptomatic and associated with low median survival.

The SUL compounds have a unique mechanism-of-action and the potential to revolutionize the standard-of-care of diseases associated with a declined mitochondrial function.